25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

MTNB (Matinas BioPharma Holdings Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Matinas BioPharma Holdings Inc together

I guess you are interested in Matinas BioPharma Holdings Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Matinas BioPharma Holdings Inc’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Matinas BioPharma Holdings Inc’s Price Targets

I'm going to help you getting a better view of Matinas BioPharma Holdings Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Matinas BioPharma Holdings Inc

I send you an email if I find something interesting about Matinas BioPharma Holdings Inc.

1. Quick Overview

1.1. Quick analysis of Matinas BioPharma Holdings Inc (30 sec.)










1.2. What can you expect buying and holding a share of Matinas BioPharma Holdings Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
20.0%

What is your share worth?

Current worth
$1.49
Expected worth in 1 year
$0.12
How sure are you?
27.5%

+ What do you gain per year?

Total Gains per Share
$-1.37
Return On Investment
-224.6%

For what price can you sell your share?

Current Price per Share
$0.61
Expected price per share
$0.478 - $0.75
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Matinas BioPharma Holdings Inc (5 min.)




Live pricePrice per Share (EOD)
$0.61
Intrinsic Value Per Share
$-83.10 - $-8.31
Total Value Per Share
$-81.61 - $-6.82

2.2. Growth of Matinas BioPharma Holdings Inc (5 min.)




Is Matinas BioPharma Holdings Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$7.5m$21.2m-$8.6m-69.4%

How much money is Matinas BioPharma Holdings Inc making?

Current yearPrevious yearGrowGrow %
Making money-$6.7m-$5.8m-$901.7k-13.4%
Net Profit Margin0.0%121.2%--

How much money comes from the company's main activities?

2.3. Financial Health of Matinas BioPharma Holdings Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#628 / 892

Most Revenue
#741 / 892

Most Profit
#432 / 892

Most Efficient
#190 / 892
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Matinas BioPharma Holdings Inc?

Welcome investor! Matinas BioPharma Holdings Inc's management wants to use your money to grow the business. In return you get a share of Matinas BioPharma Holdings Inc.

First you should know what it really means to hold a share of Matinas BioPharma Holdings Inc. And how you can make/lose money.

Speculation

The Price per Share of Matinas BioPharma Holdings Inc is $0.61. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Matinas BioPharma Holdings Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Matinas BioPharma Holdings Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.49. Based on the TTM, the Book Value Change Per Share is $-0.34 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.89 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Matinas BioPharma Holdings Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.66-271.8%-1.32-216.4%-1.14-187.3%-1.16-189.7%-1.16-190.3%-1.06-173.4%
Usd Book Value Change Per Share0.000.0%-0.34-56.1%-0.89-145.6%-0.66-107.7%-0.69-112.8%0.011.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.034.9%13.942,285.3%
Usd Total Gains Per Share0.000.0%-0.34-56.1%-0.89-145.6%-0.66-107.7%-0.66-107.9%13.952,286.3%
Usd Price Per Share0.52-1.18-0.24-0.68-0.80-0.96-
Price to Earnings Ratio-0.08--0.31--0.05--0.17--0.19--0.33-
Price-to-Total Gains Ratio354,578.22-88,643.16--0.28-29,547.34-17,728.07-8,863.42-
Price to Book Ratio0.35-0.47-0.06-0.20-0.15-0.44-
Price-to-Total Gains Ratio354,578.22-88,643.16--0.28-29,547.34-17,728.07-8,863.42-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.61
Number of shares1639
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.03
Usd Book Value Change Per Share-0.34-0.69
Usd Total Gains Per Share-0.34-0.66
Gains per Quarter (1639 shares)-561.26-1,078.70
Gains per Year (1639 shares)-2,245.06-4,314.79
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-2245-2255197-4512-4325
20-4490-4500394-9023-8640
30-6735-6745590-13535-12955
40-8980-8990787-18046-17270
50-11225-11235984-22558-21585
60-13470-134801181-27069-25900
70-15715-157251377-31581-30215
80-17960-179701574-36093-34530
90-20205-202151771-40604-38845
100-22451-224601968-45116-43160

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%2.038.00.05.0%2.048.00.04.0%
Book Value Change Per Share2.02.00.050.0%2.010.00.016.7%3.017.00.015.0%9.031.00.022.5%13.036.01.026.0%
Dividend per Share0.00.04.00.0%1.00.011.08.3%5.00.015.025.0%8.00.032.020.0%8.00.042.016.0%
Total Gains per Share2.02.00.050.0%2.010.00.016.7%3.017.00.015.0%11.029.00.027.5%15.034.01.030.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Matinas BioPharma Holdings Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.000-0.342+23350635%-0.888+60544605%-0.657+44784016%-0.688+46924353%0.006-100%
Book Value Per Share--1.4922.460-39%4.168-64%4.679-68%7.649-80%5.625-73%
Current Ratio--3.0104.485-33%6.635-55%6.897-56%11.730-74%9.492-68%
Debt To Asset Ratio--0.4000.312+28%0.342+17%0.276+45%0.209+91%0.221+81%
Debt To Equity Ratio--0.6650.478+39%0.816-18%0.502+33%0.350+90%0.335+98%
Dividend Per Share----0%-0%0.000-100%0.030-100%13.941-100%
Enterprise Value--4878229.6009070692.521-46%867499.214+462%12066817.585-60%29164236.218-83%24780342.939-80%
Eps---1.658-1.320-20%-1.143-31%-1.157-30%-1.161-30%-1.058-36%
Ev To Ebitda Ratio---0.322-0.737+129%-0.030-91%-0.653+103%-1.357+322%-1.312+308%
Free Cash Flow Per Share---0.690-0.670-3%-0.844+22%-0.813+18%-0.817+18%-2.653+285%
Free Cash Flow To Equity Per Share---0.690-0.221-68%-0.842+22%-0.663-4%-0.652-6%-2.021+193%
Gross Profit Margin--1.0001.011-1%1.022-2%1.011-1%1.006-1%1.0030%
Intrinsic Value_10Y_max---8.308----------
Intrinsic Value_10Y_min---83.102----------
Intrinsic Value_1Y_max---2.906----------
Intrinsic Value_1Y_min---10.291----------
Intrinsic Value_3Y_max---7.152----------
Intrinsic Value_3Y_min---29.403----------
Intrinsic Value_5Y_max---9.492----------
Intrinsic Value_5Y_min---46.705----------
Market Cap3103057.800+15%2645229.6006013192.521-56%1242749.214+113%3434347.585-23%4054272.318-35%6529587.164-59%
Net Profit Margin----0%1.212-100%-0.9050%-5.8340%-22.4780%
Operating Margin----0%1.356-100%-1.3000%-8.5010%-24.7260%
Operating Ratio----0%-1.3430%1.960-100%14.357-100%38.458-100%
Pb Ratio0.409+15%0.3490.468-26%0.062+466%0.203+71%0.155+125%0.441-21%
Pe Ratio-0.092-17%-0.078-0.311+296%-0.053-32%-0.172+119%-0.187+138%-0.332+323%
Price Per Share0.610+15%0.5201.182-56%0.244+113%0.675-23%0.797-35%0.955-46%
Price To Free Cash Flow Ratio-0.221-17%-0.188-0.431+129%-0.087-54%-0.226+20%-0.292+55%-0.588+212%
Price To Total Gains Ratio415947.523+15%354578.21688643.165+300%-0.275+100%29547.340+1100%17728.073+1900%8863.422+3900%
Quick Ratio--2.7324.564-40%9.805-72%9.673-72%18.178-85%13.197-79%
Return On Assets---0.667-0.444-33%-0.190-72%-0.242-64%-0.177-74%-0.186-72%
Return On Equity---1.111-0.698-37%-0.289-74%-0.366-67%-0.255-77%-0.262-76%
Total Gains Per Share--0.000-0.342+23350635%-0.888+60544605%-0.657+44783031%-0.658+44877708%13.947-100%
Usd Book Value--7590000.00012515500.000-39%21202000.000-64%23799950.083-68%38912443.250-80%28999920.925-74%
Usd Book Value Change Per Share--0.000-0.342+23350635%-0.888+60544605%-0.657+44784016%-0.688+46924353%0.006-100%
Usd Book Value Per Share--1.4922.460-39%4.168-64%4.679-68%7.649-80%5.625-73%
Usd Dividend Per Share----0%-0%0.000-100%0.030-100%13.941-100%
Usd Enterprise Value--4878229.6009070692.521-46%867499.214+462%12066817.585-60%29164236.218-83%24780342.939-80%
Usd Eps---1.658-1.320-20%-1.143-31%-1.157-30%-1.161-30%-1.058-36%
Usd Free Cash Flow---3510000.000-3406500.000-3%-4294500.000+22%-4136563.833+18%-4156018.800+18%-13560677.800+286%
Usd Free Cash Flow Per Share---0.690-0.670-3%-0.844+22%-0.813+18%-0.817+18%-2.653+285%
Usd Free Cash Flow To Equity Per Share---0.690-0.221-68%-0.842+22%-0.663-4%-0.652-6%-2.021+193%
Usd Market Cap3103057.800+15%2645229.6006013192.521-56%1242749.214+113%3434347.585-23%4054272.318-35%6529587.164-59%
Usd Price Per Share0.610+15%0.5201.182-56%0.244+113%0.675-23%0.797-35%0.955-46%
Usd Profit---8433000.000-6715000.000-20%-5813250.000-31%-5580490.583-34%-5507517.750-35%-4407569.025-48%
Usd Revenue----0%-274000.0000%265666.667-100%167318.300-100%147999.500-100%
Usd Total Gains Per Share--0.000-0.342+23350635%-0.888+60544605%-0.657+44783031%-0.658+44877708%13.947-100%
 EOD+6 -2MRQTTM+8 -25YOY+18 -173Y+11 -265Y+11 -2610Y+10 -27

3.3 Fundamental Score

Let's check the fundamental score of Matinas BioPharma Holdings Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.092
Price to Book Ratio (EOD)Between0-10.409
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.732
Current Ratio (MRQ)Greater than13.010
Debt to Asset Ratio (MRQ)Less than10.400
Debt to Equity Ratio (MRQ)Less than10.665
Return on Equity (MRQ)Greater than0.15-1.111
Return on Assets (MRQ)Greater than0.05-0.667
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Matinas BioPharma Holdings Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.353
Ma 20Greater thanMa 500.579
Ma 50Greater thanMa 1000.569
Ma 100Greater thanMa 2000.583
OpenGreater thanClose0.592
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Matinas BioPharma Holdings Inc

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It also offers MAT2501, an orally administered formulation of amikacin to treat chronic and acute bacterial infections, as well as non-tuberculosis mycobacterium. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases for the development of oral formulations of Gilead's remdesivir; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.

Fundamental data was last updated by Penke on 2025-04-24 19:53:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Matinas BioPharma Holdings Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Matinas BioPharma Holdings Inc to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Matinas BioPharma Holdings Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY121.2%-121.2%
TTM-5Y-583.4%+583.4%
5Y-583.4%10Y-2,247.8%+1,664.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--93.6%+93.6%
TTM--180.4%+180.4%
YOY121.2%-196.9%+318.1%
3Y-90.5%-244.6%+154.1%
5Y-583.4%-350.0%-233.4%
10Y-2,247.8%-486.0%-1,761.8%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Matinas BioPharma Holdings Inc is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Matinas BioPharma Holdings Inc to theΒ Biotechnology industry mean.
  • -66.7% Return on Assets means thatΒ Matinas BioPharma Holdings Inc generatedΒ $-0.67 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Matinas BioPharma Holdings Inc:

  • The MRQ is -66.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -44.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-66.7%TTM-44.4%-22.3%
TTM-44.4%YOY-19.0%-25.4%
TTM-44.4%5Y-17.7%-26.8%
5Y-17.7%10Y-18.6%+1.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-66.7%-11.7%-55.0%
TTM-44.4%-12.0%-32.4%
YOY-19.0%-11.7%-7.3%
3Y-24.2%-12.1%-12.1%
5Y-17.7%-12.9%-4.8%
10Y-18.6%-14.5%-4.1%
4.3.1.3. Return on Equity

Shows how efficient Matinas BioPharma Holdings Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Matinas BioPharma Holdings Inc to theΒ Biotechnology industry mean.
  • -111.1% Return on Equity means Matinas BioPharma Holdings Inc generated $-1.11Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Matinas BioPharma Holdings Inc:

  • The MRQ is -111.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -69.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-111.1%TTM-69.8%-41.3%
TTM-69.8%YOY-28.9%-40.9%
TTM-69.8%5Y-25.5%-44.3%
5Y-25.5%10Y-26.2%+0.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-111.1%-15.5%-95.6%
TTM-69.8%-15.8%-54.0%
YOY-28.9%-15.5%-13.4%
3Y-36.6%-17.7%-18.9%
5Y-25.5%-18.4%-7.1%
10Y-26.2%-20.8%-5.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Matinas BioPharma Holdings Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Matinas BioPharma Holdings Inc is operatingΒ .

  • Measures how much profit Matinas BioPharma Holdings Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Matinas BioPharma Holdings Inc to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Matinas BioPharma Holdings Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY135.6%-135.6%
TTM-5Y-850.1%+850.1%
5Y-850.1%10Y-2,472.6%+1,622.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--187.8%+187.8%
TTM--285.2%+285.2%
YOY135.6%-208.0%+343.6%
3Y-130.0%-247.4%+117.4%
5Y-850.1%-360.9%-489.2%
10Y-2,472.6%-464.7%-2,007.9%
4.3.2.2. Operating Ratio

Measures how efficient Matinas BioPharma Holdings Inc is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Matinas BioPharma Holdings Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-1.343+1.343
TTM-5Y14.357-14.357
5Y14.35710Y38.458-24.101
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.126-2.126
TTM-3.019-3.019
YOY-1.3432.886-4.229
3Y1.9603.487-1.527
5Y14.3574.862+9.495
10Y38.4586.533+31.925
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Matinas BioPharma Holdings Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Matinas BioPharma Holdings Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 3.01Β means the company has $3.01 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Matinas BioPharma Holdings Inc:

  • The MRQ is 3.010. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.485. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.010TTM4.485-1.474
TTM4.485YOY6.635-2.150
TTM4.4855Y11.730-7.246
5Y11.73010Y9.492+2.238
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.0103.588-0.578
TTM4.4853.910+0.575
YOY6.6354.280+2.355
3Y6.8974.801+2.096
5Y11.7305.833+5.897
10Y9.4926.244+3.248
4.4.3.2. Quick Ratio

Measures if Matinas BioPharma Holdings Inc is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Matinas BioPharma Holdings Inc to theΒ Biotechnology industry mean.
  • A Quick Ratio of 2.73Β means the company can pay off $2.73 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Matinas BioPharma Holdings Inc:

  • The MRQ is 2.732. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.564. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.732TTM4.564-1.832
TTM4.564YOY9.805-5.241
TTM4.5645Y18.178-13.614
5Y18.17810Y13.197+4.980
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.7322.848-0.116
TTM4.5643.430+1.134
YOY9.8054.128+5.677
3Y9.6734.685+4.988
5Y18.1785.882+12.296
10Y13.1976.550+6.647
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Matinas BioPharma Holdings Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Matinas BioPharma Holdings IncΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Matinas BioPharma Holdings Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.40Β means that Matinas BioPharma Holdings Inc assets areΒ financed with 40.0% credit (debt) and the remaining percentage (100% - 40.0%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Matinas BioPharma Holdings Inc:

  • The MRQ is 0.400. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.312. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.400TTM0.312+0.088
TTM0.312YOY0.342-0.030
TTM0.3125Y0.209+0.103
5Y0.20910Y0.221-0.011
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4000.342+0.058
TTM0.3120.341-0.029
YOY0.3420.330+0.012
3Y0.2760.330-0.054
5Y0.2090.359-0.150
10Y0.2210.382-0.161
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Matinas BioPharma Holdings Inc is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Matinas BioPharma Holdings Inc to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 66.5% means that company has $0.67 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Matinas BioPharma Holdings Inc:

  • The MRQ is 0.665. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.478. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.665TTM0.478+0.188
TTM0.478YOY0.816-0.338
TTM0.4785Y0.350+0.127
5Y0.35010Y0.335+0.015
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6650.408+0.257
TTM0.4780.427+0.051
YOY0.8160.406+0.410
3Y0.5020.440+0.062
5Y0.3500.449-0.099
10Y0.3350.506-0.171
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Matinas BioPharma Holdings Inc generates.

  • Above 15 is considered overpriced butΒ always compareΒ Matinas BioPharma Holdings Inc to theΒ Biotechnology industry mean.
  • A PE ratio of -0.08 means the investor is paying $-0.08Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Matinas BioPharma Holdings Inc:

  • The EOD is -0.092. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.078. Based on the earnings, the company is expensive. -2
  • The TTM is -0.311. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.092MRQ-0.078-0.014
MRQ-0.078TTM-0.311+0.232
TTM-0.311YOY-0.053-0.257
TTM-0.3115Y-0.187-0.124
5Y-0.18710Y-0.332+0.145
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.092-1.965+1.873
MRQ-0.078-2.553+2.475
TTM-0.311-3.216+2.905
YOY-0.053-3.402+3.349
3Y-0.172-4.122+3.950
5Y-0.187-6.344+6.157
10Y-0.332-7.002+6.670
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Matinas BioPharma Holdings Inc:

  • The EOD is -0.221. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.188. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.431. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.221MRQ-0.188-0.033
MRQ-0.188TTM-0.431+0.243
TTM-0.431YOY-0.087-0.344
TTM-0.4315Y-0.292-0.140
5Y-0.29210Y-0.588+0.297
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.221-2.660+2.439
MRQ-0.188-3.481+3.293
TTM-0.431-4.076+3.645
YOY-0.087-4.319+4.232
3Y-0.226-5.522+5.296
5Y-0.292-8.511+8.219
10Y-0.588-9.706+9.118
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Matinas BioPharma Holdings Inc is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 0.35 means the investor is paying $0.35Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Matinas BioPharma Holdings Inc:

  • The EOD is 0.409. Based on the equity, the company is cheap. +2
  • The MRQ is 0.349. Based on the equity, the company is cheap. +2
  • The TTM is 0.468. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.409MRQ0.349+0.060
MRQ0.349TTM0.468-0.120
TTM0.468YOY0.062+0.407
TTM0.4685Y0.155+0.313
5Y0.15510Y0.441-0.286
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.4091.828-1.419
MRQ0.3492.268-1.919
TTM0.4682.425-1.957
YOY0.0622.517-2.455
3Y0.2032.904-2.701
5Y0.1553.775-3.620
10Y0.4414.380-3.939
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Matinas BioPharma Holdings Inc.

3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets12,641
Total Liabilities5,051
Total Stockholder Equity7,590
 As reported
Total Liabilities 5,051
Total Stockholder Equity+ 7,590
Total Assets = 12,641

Assets

Total Assets12,641
Total Current Assets8,025
Long-term Assets4,616
Total Current Assets
Cash And Cash Equivalents 7,284
Other Current Assets 741
Total Current Assets  (as reported)8,025
Total Current Assets  (calculated)8,025
+/-0
Long-term Assets
Property Plant Equipment 2,156
Intangible Assets 2,260
Long-term Assets Other 200
Long-term Assets  (as reported)4,616
Long-term Assets  (calculated)4,616
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities2,666
Long-term Liabilities2,385
Total Stockholder Equity7,590
Total Current Liabilities
Short-term Debt 766
Accounts payable 95
Other Current Liabilities 1,805
Total Current Liabilities  (as reported)2,666
Total Current Liabilities  (calculated)2,666
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)2,385
Long-term Liabilities  (calculated)0
+/- 2,385
Total Stockholder Equity
Common Stock1
Retained Earnings -199,824
Other Stockholders Equity 207,413
Total Stockholder Equity (as reported)7,590
Total Stockholder Equity (calculated)7,590
+/-0
Other
Cash and Short Term Investments 7,284
Common Stock Shares Outstanding 4,866
Liabilities and Stockholders Equity 12,641
Net Debt -4,390
Net Working Capital 5,359
Short Long Term Debt Total 2,894



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-30
> Total Assets 
0
424
0
697
12,631
11,334
9,327
7,363
5,789
3,361
9,798
11,862
9,869
8,406
6,746
5,565
11,307
9,816
22,032
17,800
16,524
14,424
11,489
16,044
14,412
19,943
50,572
48,215
44,816
40,240
84,113
79,087
74,806
70,967
72,351
69,971
66,985
61,326
55,785
52,416
47,546
44,819
38,262
34,025
29,791
65,578
19,610
24,365
20,577
12,641
12,641
12,64112,64120,57724,36519,61065,57829,79134,02538,26244,81947,54652,41655,78561,32666,98569,97172,35170,96774,80679,08784,11340,24044,81648,21550,57219,94314,41216,04411,48914,42416,52417,80022,0329,81611,3075,5656,7468,4069,86911,8629,7983,3615,7897,3639,32711,33412,63169704240
   > Total Current Assets 
0
424
424
507
12,603
10,925
8,646
6,686
5,115
2,805
4,840
6,880
4,885
3,559
1,912
774
6,529
4,565
16,793
11,739
10,173
7,964
4,894
9,343
7,525
13,085
39,904
37,426
34,251
29,923
73,989
69,209
65,203
61,555
63,136
60,939
56,481
50,993
45,119
41,924
37,099
34,532
28,206
24,000
19,989
15,543
10,289
15,285
11,741
8,025
8,025
8,0258,02511,74115,28510,28915,54319,98924,00028,20634,53237,09941,92445,11950,99356,48160,93963,13661,55565,20369,20973,98929,92334,25137,42639,90413,0857,5259,3434,8947,96410,17311,73916,7934,5656,5297741,9123,5594,8856,8804,8402,8055,1156,6868,64610,92512,6035074244240
       Cash And Cash Equivalents 
0
424
-424
462
12,573
10,840
8,558
6,647
5,007
2,591
4,617
6,605
4,363
3,227
1,673
578
6,220
4,105
15,835
11,266
9,001
7,307
4,263
8,903
6,632
12,447
39,413
36,831
32,665
22,170
10,078
14,904
7,051
12,432
23,383
30,352
24,923
21,030
19,328
10,399
11,176
6,830
5,739
9,743
6,407
4,837
1,121
4,216
10,295
7,284
7,284
7,2847,28410,2954,2161,1214,8376,4079,7435,7396,83011,17610,39919,32821,03024,92330,35223,38312,4327,05114,90410,07822,17032,66536,83139,41312,4476,6328,9034,2637,3079,00111,26615,8354,1056,2205781,6733,2274,3636,6054,6172,5915,0076,6478,55810,84012,573462-4244240
       Short-term Investments 
0
0
849
0
0
0
0
0
0
100
100
100
100
100
100
56
56
156
155
155
155
155
155
100
200
0
0
0
0
5,605
61,090
53,054
55,720
46,247
37,284
29,490
28,907
28,592
24,542
28,104
21,875
21,933
19,118
12,770
11,809
8,969
7,039
10,097
500
0
0
0050010,0977,0398,96911,80912,77019,11821,93321,87528,10424,54228,59228,90729,49037,28446,24755,72053,05461,0905,6050000200100155155155155155156565610010010010010010000000084900
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
30
60
80
0
0
0
0
0
0
0
0
0
0
90
0
0
0
0
0
0
0
0
0
650
1,300
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000001,3006500000000009000000000008060300000000000
       Other Current Assets 
0
0
0
45
30
84
88
38
108
214
194
215
442
332
238
195
310
460
959
473
1,173
657
631
350
892
639
491
595
1,586
2,148
2,821
1,251
2,432
2,876
2,469
1,096
2,651
1,371
1,249
3,422
4,048
11,488
6,648
2,924
3,496
3,524
2,179
972
946
691
741
7416919469722,1793,5243,4962,9246,64811,4884,0483,4221,2491,3712,6511,0962,4692,8762,4321,2512,8212,1481,5865954916398923506316571,1734739594603101952383324422151942141083888843045000
   > Long-term Assets 
0
0
-424
190
28
409
681
678
674
556
4,957
4,982
4,984
4,847
4,834
4,791
4,778
5,251
5,238
6,061
6,350
6,460
6,596
6,701
6,887
6,858
10,669
10,789
10,565
10,317
10,124
9,878
9,603
9,412
9,215
9,032
10,504
10,333
10,666
10,491
10,447
10,287
10,056
10,025
9,802
50,035
9,321
9,080
8,836
4,616
4,616
4,6164,6168,8369,0809,32150,0359,80210,02510,05610,28710,44710,49110,66610,33310,5049,0329,2159,4129,6039,87810,12410,31710,56510,78910,6696,8586,8876,7016,5966,4606,3506,0615,2385,2514,7784,7914,8344,8474,9844,9824,95755667467868140928190-42400
       Property Plant Equipment 
0
0
0
0
28
93
365
362
357
340
339
363
366
378
365
382
369
356
344
1,171
1,461
1,570
1,706
1,811
2,097
2,043
5,828
5,949
5,825
5,628
5,435
5,239
5,050
4,859
4,661
4,479
5,950
5,779
6,112
5,938
5,893
5,734
5,503
5,472
5,249
5,008
4,768
4,527
2,635
2,156
2,156
2,1562,1562,6354,5274,7685,0085,2495,4725,5035,7345,8935,9386,1125,7795,9504,4794,6614,8595,0505,2395,4355,6285,8255,9495,8282,0432,0971,8111,7061,5701,4611,17134435636938236537836636333934035736236593280000
       Goodwill 
0
0
0
0
0
0
0
0
0
1,336
1,385
1,385
1,385
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
0
0
001,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3851,3851,3851,336000000000
       Long Term Investments 
0
0
0
0
0
0
316
316
316
216
216
216
217
115
115
55
55
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000005555115115217216216216316316316000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
2,260
2,260
2,2602,2603,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0170000000000
       Other Assets 
0
0
0
0
0
0
316
316
316
216
4,618
4,619
4,619
4,469
4,468
4,409
4,409
4,895
4,895
4,890
4,890
4,890
3,553
3,553
3,453
3,478
486
3,503
3,403
3,353
3,353
3,303
3,217
3,217
3,217
3,217
3,217
3,217
3,217
3,217
3,217
3,217
0
3,217
0
0
0
0
0
0
0
00000003,21703,2173,2173,2173,2173,2173,2173,2173,2173,2173,2173,3033,3533,3533,4033,5034863,4783,4533,5533,5534,8904,8904,8904,8954,8954,4094,4094,4684,4694,6194,6194,618216316316316000000
> Total Liabilities 
0
84
0
316
502
859
717
906
1,043
1,134
3,405
3,233
2,908
2,334
2,525
2,567
2,585
2,666
3,172
2,592
3,739
3,742
3,056
3,517
4,112
3,802
7,567
7,797
6,835
7,189
6,510
6,262
6,601
7,237
5,794
7,068
8,731
8,833
8,103
9,567
8,927
8,182
5,637
6,171
6,641
46,332
5,052
5,262
4,798
5,051
5,051
5,0515,0514,7985,2625,05246,3326,6416,1715,6378,1828,9279,5678,1038,8338,7317,0685,7947,2376,6016,2626,5107,1896,8357,7977,5673,8024,1123,5173,0563,7423,7392,5923,1722,6662,5852,5672,5252,3342,9083,2333,4051,1341,0439067178595023160840
   > Total Current Liabilities 
0
84
0
316
502
859
673
872
1,021
1,118
1,308
1,136
873
1,129
1,320
1,342
1,361
1,445
1,953
1,335
1,883
2,225
1,030
1,490
2,639
2,840
3,116
3,464
2,622
3,097
2,543
2,408
2,838
3,568
2,221
3,591
4,099
4,349
3,768
5,382
4,902
4,286
1,896
2,589
3,229
2,622
1,998
2,392
2,124
2,666
2,666
2,6662,6662,1242,3921,9982,6223,2292,5891,8964,2864,9025,3823,7684,3494,0993,5912,2213,5682,8382,4082,5433,0972,6223,4643,1162,8402,6391,4901,0302,2251,8831,3351,9531,4451,3611,3421,3201,1298731,1361,3081,1181,0218726738595023160840
       Short-term Debt 
0
0
0
0
0
0
45
44
44
44
55
44
32
11
0
10
199
128
57
19
317
197
94
53
403
200
536
466
474
478
484
478
450
422
394
378
543
560
576
591
548
569
1,178
1,226
1,274
1,322
686
1,424
738
0
766
76607381,4246861,3221,2741,2261,178569548591576560543378394422450478484478474466536200403539419731719571281991001132445544444445000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
60
0
0
0
11
0
10
199
144
57
70
365
27
52
53
83
83
80
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000080838353522736570571441991001100060000000000
       Accounts payable 
0
60
0
273
261
397
242
281
212
271
467
746
282
498
621
476
209
476
1,247
453
342
583
474
497
303
2,557
395
548
686
679
953
495
373
350
422
450
662
937
1,352
497
657
618
516
604
835
514
473
238
349
95
95
95953492384735148356045166186574971,3529376624504223503734959536796865483952,5573034974745833424531,2474762094766214982827464672712122812423972612730600
       Other Current Liabilities 
0
24
0
43
241
462
386
547
765
803
787
347
558
619
699
856
953
841
483
743
1,149
1,415
462
940
1,933
1,174
2,185
2,449
1,463
1,840
906
1,235
1,911
2,795
1,406
2,763
2,894
2,852
1,841
4,294
3,697
3,099
202
759
1,120
786
839
730
1,037
4
1,805
1,80541,0377308397861,1207592023,0993,6974,2941,8412,8522,8942,7631,4062,7951,9111,2359061,8401,4632,4492,1851,1741,9339404621,4151,149743483841953856699619558347787803765547386462241430240
   > Long-term Liabilities 
0
0
0
0
0
0
44
34
22
15
2,097
2,097
2,035
1,205
1,205
1,226
1,224
1,222
1,219
1,257
1,856
1,517
2,026
2,028
1,473
962
4,451
4,333
4,213
4,092
3,967
3,854
3,763
3,669
3,573
3,476
4,632
4,484
4,335
4,185
4,025
3,896
3,741
3,582
3,412
43,710
3,054
2,870
2,674
2,385
2,385
2,3852,3852,6742,8703,05443,7103,4123,5823,7413,8964,0254,1854,3354,4844,6323,4763,5733,6693,7633,8543,9674,0924,2134,3334,4519621,4732,0282,0261,5171,8561,2571,2191,2221,2241,2261,2051,2052,0352,0972,09715223444000000
       Long term Debt Total 
0
0
0
0
0
0
44
34
22
15
0
0
0
0
0
21
0
0
0
0
0
0
0
0
0
108
89
73
62
55
47
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000004755627389108000000000210000015223444000000
       Other Liabilities 
0
0
0
0
0
0
44
34
22
0
843
844
782
1,205
0
0
0
1,205
1,205
1,205
603
601
1,910
1,924
1,350
854
341
341
341
341
341
341
341
341
341
341
341
341
341
341
341
341
0
341
0
0
0
0
0
0
0
000000034103413413413413413413413413413413413413413413413418541,3501,9241,9106016031,2051,2051,2050001,2057828448430223444000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
1,205
0
0
0
3,017
0
1,205
1,205
3,017
1,205
3,017
3,017
3,017
3,017
3,017
3,017
854
3,017
3,017
3,017
3,017
3,017
3,017
341
3,017
341
3,017
341
341
341
341
341
341
341
341
0
0
0
0
0
0
0
00000003413413413413413413413413,0173413,0173413,0173,0173,0173,0173,0173,0178543,0173,0173,0173,0173,0173,0171,2053,0171,2051,20503,0170001,205000000000
> Total Stockholder Equity
0
340
340
380
12,128
10,475
8,610
6,457
4,746
2,228
6,393
8,629
6,961
6,072
4,220
2,997
8,722
7,150
18,860
15,208
12,785
10,682
8,434
12,527
10,300
16,142
43,006
40,418
37,981
33,051
77,603
72,825
68,205
63,731
66,556
62,904
58,254
52,493
47,682
42,849
38,619
36,637
32,625
27,854
23,150
19,246
14,558
19,103
15,779
7,590
7,590
7,5907,59015,77919,10314,55819,24623,15027,85432,62536,63738,61942,84947,68252,49358,25462,90466,55663,73168,20572,82577,60333,05137,98140,41843,00616,14210,30012,5278,43410,68212,78515,20818,8607,1508,7222,9974,2206,0726,9618,6296,3932,2284,7466,4578,61010,47512,1283803403400
   Common Stock
0
1
0
1
3
3
3
3
3
3
5
6
6
6
6
6
6
6
9
9
9
9
9
9
10
11
14
14
16
16
20
20
20
20
20
21
22
22
22
22
22
22
22
22
22
22
22
25
1
0
1
101252222222222222222222222212020202020161614141110999999666666653333331010
   Retained Earnings Total Equity0000000-164,204-158,144-152,631-148,997-143,535-137,612-131,634-124,935-118,098-112,464-107,507-101,166-95,717-89,423-84,378-78,805-73,813-69,995-65,94500000000-33,288-27,056-25,432-23,187-21,181-19,026-16,622-14,052-11,007-8,396-5,970000000
   Accumulated Other Comprehensive Income 
0
0
-117
0
0
-1
0
0
-66
-43
-43
0
0
-87
-100
-114
-127
-140
-152
-165
-196
-241
-288
-341
-397
-439
-415
-464
-509
-1
522
478
364
228
136
51
-2
-145
-629
-754
-936
-824
-595
-514
-359
-221
-134
-51
0
0
0
000-51-134-221-359-514-595-824-936-754-629-145-251136228364478522-1-509-464-415-439-397-341-288-241-196-165-152-140-127-114-100-8700-43-43-6600-100-11700
   Capital Surplus 
0
0
0
0
0
0
14,576
14,850
15,750
16,276
23,010
27,650
28,136
29,254
29,647
30,047
35,918
0
0
0
0
0
0
0
0
72,295
103,284
104,601
112,746
113,428
162,520
164,080
165,024
167,192
175,190
180,929
183,169
184,251
185,902
187,116
188,529
190,070
191,342
192,550
0
0
0
0
0
0
0
0000000192,550191,342190,070188,529187,116185,902184,251183,169180,929175,190167,192165,024164,080162,520113,428112,746104,601103,28472,2950000000035,91830,04729,64729,25428,13627,65023,01016,27615,75014,85014,576000000
   Treasury Stock000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
14,155
14,302
14,576
14,850
15,750
16,276
23,010
27,650
28,136
29,254
29,647
30,047
35,918
36,238
52,478
53,045
54,686
56,230
58,206
58,784
60,927
0
103,284
104,601
112,746
113,428
162,520
164,080
165,024
167,192
175,190
180,929
183,169
184,251
185,902
187,116
188,529
190,070
191,342
192,550
193,746
195,018
196,067
206,245
207,169
0
207,413
207,4130207,169206,245196,067195,018193,746192,550191,342190,070188,529187,116185,902184,251183,169180,929175,190167,192165,024164,080162,520113,428112,746104,601103,284060,92758,78458,20656,23054,68653,04552,47836,23835,91830,04729,64729,25428,13627,65023,01016,27615,75014,85014,57614,30214,1550000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-20,162
Operating Income-24,593-20,162
 
Operating Expense (+$)
Research Development11,433
Selling General Administrative8,729
Selling And Marketing Expenses0
Operating Expense20,16220,162
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-24,593
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-24,251-24,935
EBIT - interestExpense = 0
-24,251
-24,251
Interest Expense0
Earnings Before Interest and Taxes (EBIT)0-24,251
Earnings Before Interest and Taxes (EBITDA)-24,593
 
After tax Income (+$)
Income Before Tax-24,251
Tax Provision--80
Net Income From Continuing Ops-24,251-24,171
Net Income-24,251
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses24,593
Total Other Income/Expenses Net3420
 

Technical Analysis of Matinas BioPharma Holdings Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Matinas BioPharma Holdings Inc. The general trend of Matinas BioPharma Holdings Inc is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Matinas BioPharma Holdings Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Matinas BioPharma Holdings Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Matinas BioPharma Holdings Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.67 < 0.72 < 0.75.

The bearish price targets are: 0.6099 > 0.6 > 0.478.

Know someone who trades $MTNB? Share this with them.πŸ‘‡

Matinas BioPharma Holdings Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Matinas BioPharma Holdings Inc. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Matinas BioPharma Holdings Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Matinas BioPharma Holdings Inc. The current macd is 0.01682249.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Matinas BioPharma Holdings Inc price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Matinas BioPharma Holdings Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Matinas BioPharma Holdings Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Matinas BioPharma Holdings Inc Daily Moving Average Convergence/Divergence (MACD) ChartMatinas BioPharma Holdings Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Matinas BioPharma Holdings Inc. The current adx is 27.93.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Matinas BioPharma Holdings Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Matinas BioPharma Holdings Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Matinas BioPharma Holdings Inc. The current sar is 0.52607406.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Matinas BioPharma Holdings Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Matinas BioPharma Holdings Inc. The current rsi is 53.35. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending down: The RSI is trending down. -1
Matinas BioPharma Holdings Inc Daily Relative Strength Index (RSI) ChartMatinas BioPharma Holdings Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Matinas BioPharma Holdings Inc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Matinas BioPharma Holdings Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Matinas BioPharma Holdings Inc Daily Stochastic Oscillator ChartMatinas BioPharma Holdings Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Matinas BioPharma Holdings Inc. The current cci is 83.15.

Matinas BioPharma Holdings Inc Daily Commodity Channel Index (CCI) ChartMatinas BioPharma Holdings Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Matinas BioPharma Holdings Inc. The current cmo is 6.06890771.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Matinas BioPharma Holdings Inc Daily Chande Momentum Oscillator (CMO) ChartMatinas BioPharma Holdings Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Matinas BioPharma Holdings Inc. The current willr is -45.11278195.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Matinas BioPharma Holdings Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Matinas BioPharma Holdings Inc Daily Williams %R ChartMatinas BioPharma Holdings Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Matinas BioPharma Holdings Inc.

Matinas BioPharma Holdings Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Matinas BioPharma Holdings Inc. The current atr is 0.05405119.

Matinas BioPharma Holdings Inc Daily Average True Range (ATR) ChartMatinas BioPharma Holdings Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Matinas BioPharma Holdings Inc. The current obv is 18,892,098.

Matinas BioPharma Holdings Inc Daily On-Balance Volume (OBV) ChartMatinas BioPharma Holdings Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Matinas BioPharma Holdings Inc. The current mfi is 65.95.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Matinas BioPharma Holdings Inc Daily Money Flow Index (MFI) ChartMatinas BioPharma Holdings Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Matinas BioPharma Holdings Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-12-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-23WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-12-24RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-12-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-31SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-01-02RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-01-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-01-06STOCH LONG EXITThe %K line crosses below the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-07STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-01-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-04STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-02-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-13MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-14MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-24CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-25BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Matinas BioPharma Holdings Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Matinas BioPharma Holdings Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.353
Ma 20Greater thanMa 500.579
Ma 50Greater thanMa 1000.569
Ma 100Greater thanMa 2000.583
OpenGreater thanClose0.592
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Matinas BioPharma Holdings Inc with someone you think should read this too:
  • Are you bullish or bearish on Matinas BioPharma Holdings Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Matinas BioPharma Holdings Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Matinas BioPharma Holdings Inc

I send you an email if I find something interesting about Matinas BioPharma Holdings Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Matinas BioPharma Holdings Inc.

Receive notifications about Matinas BioPharma Holdings Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.